Efficienty of vaccination in patients with cancer who are treated with chemotherapy.
- Conditions
- lymphoma, non-hodgkins lymphoma, NHL, vaccination, influenza, humoral response, rituximab.lymfoom, non-hodgekin's lymfoma, NHL, vaccinatie, influenza, humorale respons, rituximab.
- Registration Number
- NL-OMON23415
- Lead Sponsor
- St. Antonius Ziekenhuis Nieuwegein
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 160
Inclusion Criteria
1. Patients with non-Hodgkin’s lymphoma, treated with rituximab (with a range of 6-12 cycles) and who are in remission;
2. Completion of rituximab therapy in the last twelve months before start of the study;
Exclusion Criteria
1. Completion of rituximab therapy 7-8 months before start of the study;
2. Fever at time of vaccination;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage responders.
- Secondary Outcome Measures
Name Time Method Immunesystem components (amount of memory Bcells, lymphocyte sbsets etc).